Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the ...
Kura Oncology, Inc. remains a Buy, driven by ziftomenib's launch and promising combination trial data in AML. Learn more ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...
Cautionary Language Concerning Forward-Looking Statements ...
The once daily, oral glucagon-like peptide-1 receptor agonist was approved based on phase 3 data from ATTAIN-1 and ATTAIN-2.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of ...
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results